{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:05:07Z","timestamp":1773273907614,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100008433","name":"Consejer\u00eda de Educaci\u00f3n, Juventud y Deporte, Comunidad de Madrid","doi-asserted-by":"publisher","award":["PEJ16\/MED\/AI-1260"],"award-info":[{"award-number":["PEJ16\/MED\/AI-1260"]}],"id":[{"id":"10.13039\/501100008433","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008433","name":"Consejer\u00eda de Educaci\u00f3n, Juventud y Deporte, Comunidad de Madrid","doi-asserted-by":"publisher","award":["PEJD-2018-PRE\/BMD-8865"],"award-info":[{"award-number":["PEJD-2018-PRE\/BMD-8865"]}],"id":[{"id":"10.13039\/501100008433","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto de Investigacion Sanitaria Gregorio Mara\u00f1on","award":["PRE-2018-2"],"award-info":[{"award-number":["PRE-2018-2"]}]},{"name":"Instituto de Investigacion Sanitaria Gregorio Mara\u00f1on","award":["PI-2-2019"],"award-info":[{"award-number":["PI-2-2019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00280-020-04093-1","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T05:02:41Z","timestamp":1591851761000},"page":"45-54","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine"],"prefix":"10.1007","volume":"86","author":[{"given":"Xandra","family":"Garc\u00eda-Gonz\u00e1lez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bartosz","family":"Kaczmarczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Abarca-Zabal\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Garc\u00eda-Alfonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Robles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Pach\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngeles","family":"Vaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Salvador-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Sanjurjo-S\u00e1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3964-5837","authenticated-orcid":false,"given":"Luis A.","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"4093_CR1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1159\/000055262","volume":"57","author":"RA Brito","year":"1999","unstructured":"Brito RA, Medgyesy D, Zukowski TH et al (1999) Fluoropyrimidines: a critical evaluation. Oncology 57:2\u20138","journal-title":"Oncology"},{"key":"4093_CR2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/CAD.0000000000000453","volume":"28","author":"CE Onesti","year":"2016","unstructured":"Onesti CE, Botticelli A, La TM et al (2016) 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX. Anticancer Drugs 28:322\u2013326. https:\/\/doi.org\/10.1097\/CAD.0000000000000453","journal-title":"Anticancer Drugs"},{"key":"4093_CR3","first-page":"2203","volume":"47","author":"GD Heggie","year":"1987","unstructured":"Heggie GD, Sommadossi JP, Cross DS et al (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203\u20132206","journal-title":"Cancer Res"},{"key":"4093_CR4","first-page":"507","volume":"2","author":"M Chazal","year":"1996","unstructured":"Chazal M, Etienne MC, Ren\u00e9e N et al (1996) Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver. Clin Cancer Res 2:507\u2013510","journal-title":"Clin Cancer Res"},{"key":"4093_CR5","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1200\/JCO.1999.17.4.1105","volume":"17","author":"E Gamelin","year":"1999","unstructured":"Gamelin E, Boisdron-Celle M, Gu\u00e9rin-Meyer V et al (1999) Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 17:1105. https:\/\/doi.org\/10.1200\/JCO.1999.17.4.1105","journal-title":"J Clin Oncol"},{"key":"4093_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","volume":"249","author":"M Boisdron-Celle","year":"2007","unstructured":"Boisdron-Celle M, Remaud G, Traore S et al (2007) 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett 249:271\u2013282. https:\/\/doi.org\/10.1016\/j.canlet.2006.09.006","journal-title":"Cancer Lett"},{"key":"4093_CR7","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/bjc.2017.94","volume":"116","author":"D Meulendijks","year":"2017","unstructured":"Meulendijks D, Henricks LM, Jacobs BAW et al (2017) Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 116:1415\u20131424. https:\/\/doi.org\/10.1038\/bjc.2017.94","journal-title":"Br J Cancer"},{"key":"4093_CR8","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.2217\/pgs.11.72","volume":"12","author":"U Amstutz","year":"2011","unstructured":"Amstutz U, Froehlich TK, Largiad\u00e8r CR (2011) Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 12:1321\u20131336. https:\/\/doi.org\/10.2217\/pgs.11.72","journal-title":"Pharmacogenomics"},{"key":"4093_CR9","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS et al (2015) Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:1639\u20131650. https:\/\/doi.org\/10.1016\/S1470-2045(15)00286-7","journal-title":"Lancet Oncol"},{"key":"4093_CR10","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2217\/pgs.13.116","volume":"14","author":"S Terrazzino","year":"2013","unstructured":"Terrazzino S, Cargnin S, Del Re M et al (2846A) DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 14:1255\u20131272. https:\/\/doi.org\/10.2217\/pgs.13.116","journal-title":"Pharmacogenomics"},{"key":"4093_CR11","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","volume":"28","author":"LM Henricks","year":"2017","unstructured":"Henricks LM, Opdam FL, Beijnen JH et al (2017) DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann Oncol Off J Eur Soc Med Oncol 28:2915\u20132922. https:\/\/doi.org\/10.1093\/annonc\/mdx411","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"4093_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM et al (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210\u2013216. https:\/\/doi.org\/10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"key":"4093_CR13","unstructured":"EMA review capecitabine. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/fluorouracil-fluorouracil-related-substances-capecitabine-tegafur-flucytosine-containing-medicinal. Accessed 23 Oct 2019"},{"key":"4093_CR14","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2217\/pgs-2016-0006","volume":"17","author":"L Cortejoso","year":"2016","unstructured":"Cortejoso L, Garc\u00eda-Gonz\u00e1lez X, Garc\u00eda MI et al (2016) Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines. Pharmacogenomics 17:979\u2013984. https:\/\/doi.org\/10.2217\/pgs-2016-0006","journal-title":"Pharmacogenomics"},{"key":"4093_CR15","doi-asserted-by":"publisher","unstructured":"Karczewski KJ, Francioli LC, Tiao G, et al (2019) Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv 531210. https:\/\/doi.org\/10.1101\/531210","DOI":"10.1101\/531210"},{"key":"4093_CR16","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2217\/pgs-2017-0102","volume":"18","author":"X Garc\u00eda-Gonz\u00e1lez","year":"2017","unstructured":"Garc\u00eda-Gonz\u00e1lez X, L\u00f3pez-Fern\u00e1ndez LA (2017) Using pharmacogenetics to prevent severe adverse reactions to capecitabine. Pharmacogenomics 18:1199\u20131213. https:\/\/doi.org\/10.2217\/pgs-2017-0102","journal-title":"Pharmacogenomics"},{"key":"4093_CR17","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nmeth0410-248","volume":"7","author":"IA Adzhubei","year":"2010","unstructured":"Adzhubei IA, Schmidt S, Peshkin L et al (2010) A method and server for predicting damaging missense mutations. Nat Methods 7:248\u2013249. https:\/\/doi.org\/10.1038\/nmeth0410-248","journal-title":"Nat Methods"},{"key":"4093_CR18","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nprot.2009.86","volume":"4","author":"P Kumar","year":"2009","unstructured":"Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073\u20131081. https:\/\/doi.org\/10.1038\/nprot.2009.86","journal-title":"Nat Protoc"},{"key":"4093_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/cpt.1020","volume":"104","author":"S Shrestha","year":"2018","unstructured":"Shrestha S, Zhang C, Jerde CR et al (2018) Gene-specific variant classifier (DPYD-Varifier) to identify deleterious alleles of dihydropyrimidine dehydrogenase. Clin Pharmacol Ther 104:709\u2013718. https:\/\/doi.org\/10.1002\/cpt.1020","journal-title":"Clin Pharmacol Ther"},{"key":"4093_CR20","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.2147\/CMAR.S174470","volume":"10","author":"X Garc\u00eda-Gonz\u00e1lez","year":"2018","unstructured":"Garc\u00eda-Gonz\u00e1lez X, L\u00f3pez-Tarruella S, Garc\u00eda MI et al (2018) Severe toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase (DPYD) gene. Cancer Manag Res 10:4517\u20134522. https:\/\/doi.org\/10.2147\/CMAR.S174470","journal-title":"Cancer Manag Res"},{"key":"4093_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nprot.2015.123","volume":"11","author":"R Vaser","year":"2016","unstructured":"Vaser R, Adusumalli S, Leng SN et al (2016) SIFT missense predictions for genomes. Nat Protoc 11:1\u20139. https:\/\/doi.org\/10.1038\/nprot.2015.123","journal-title":"Nat Protoc"},{"key":"4093_CR22","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1158\/0008-5472.CAN-13-2482","volume":"74","author":"SM Offer","year":"2014","unstructured":"Offer SM, Fossum CC, Wegner NJ et al (2014) Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 74:2545\u20132554. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2482","journal-title":"Cancer Res"},{"key":"4093_CR23","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.2217\/pgs.14.126","volume":"15","author":"J Sistonen","year":"2014","unstructured":"Sistonen J, B\u00fcchel B, Froehlich TK et al (2014) Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio. Pharmacogenomics 15:1653\u20131666. https:\/\/doi.org\/10.2217\/pgs.14.126","journal-title":"Pharmacogenomics"},{"key":"4093_CR24","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1158\/0008-5472.CAN-12-3858","volume":"73","author":"SM Offer","year":"2013","unstructured":"Offer SM, Wegner NJ, Fossum C et al (2013) Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Res 73:1958\u20131968. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3858","journal-title":"Cancer Res"},{"key":"4093_CR25","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1093\/nar\/gkp215","volume":"37","author":"F-O Desmet","year":"2009","unstructured":"Desmet F-O, Hamroun D, Lalande M et al (2009) Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37:e67. https:\/\/doi.org\/10.1093\/nar\/gkp215","journal-title":"Nucleic Acids Res"},{"key":"4093_CR26","doi-asserted-by":"publisher","first-page":"W239","DOI":"10.1093\/nar\/gkl190","volume":"34","author":"V Parthiban","year":"2006","unstructured":"Parthiban V, Gromiha MM, Schomburg D (2006) CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res 34:W239\u2013W242. https:\/\/doi.org\/10.1093\/nar\/gkl190","journal-title":"Nucleic Acids Res"},{"key":"4093_CR27","doi-asserted-by":"publisher","first-page":"W478","DOI":"10.1093\/nar\/gku377","volume":"42","author":"CC Huang","year":"2014","unstructured":"Huang CC, Meng EC, Morris JH et al (2014) Enhancing UCSF Chimera through web services. Nucleic Acids Res 42:W478\u2013W484. https:\/\/doi.org\/10.1093\/nar\/gku377","journal-title":"Nucleic Acids Res"},{"key":"4093_CR28","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1093\/emboj\/20.4.650","volume":"20","author":"D Dobritzsch","year":"2001","unstructured":"Dobritzsch D, Schneider G, Schnackerz KD, Lindqvist Y (2001) Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil. EMBO J 20:650\u2013660. https:\/\/doi.org\/10.1093\/emboj\/20.4.650","journal-title":"EMBO J"},{"key":"4093_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/cpt.210","volume":"99","author":"F Thomas","year":"2016","unstructured":"Thomas F, Hennebelle I, Delmas C et al (2016) Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil\/uracil ratio. Clin Pharmacol Ther 99:235\u2013242. https:\/\/doi.org\/10.1002\/cpt.210","journal-title":"Clin Pharmacol Ther"},{"key":"4093_CR30","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","volume":"105","author":"M-A Loriot","year":"2018","unstructured":"Loriot M-A, Ciccolini J, Thomas F et al (2018) Dihydropyrimidine d\u00e9hydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks. Bull Cancer 105:397\u2013407. https:\/\/doi.org\/10.1016\/j.bulcan.2018.02.001","journal-title":"Bull Cancer"},{"key":"4093_CR31","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1042\/bj3640157","volume":"364","author":"ABP van Kuilenburg","year":"2002","unstructured":"van Kuilenburg ABP, Dobritzsch D, Meinsma R et al (2002) Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 364:157\u2013163. https:\/\/doi.org\/10.1042\/bj3640157","journal-title":"Biochem J"},{"key":"4093_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0175998","volume":"12","author":"MC Etienne-Grimaldi","year":"2017","unstructured":"Etienne-Grimaldi MC, Boyer JC, Beroud C et al (2017) New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS ONE 12:1\u201319. https:\/\/doi.org\/10.1371\/journal.pone.0175998","journal-title":"PLoS ONE"},{"key":"4093_CR33","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2217\/pgs.15.70","volume":"16","author":"LM Henricks","year":"2015","unstructured":"Henricks LM, Meulendijks D, Swen JJ (2015) Translating DPYD genotype into DPD phenotype: using the DPYD gene activiy score. Pharmacogenomics 16:1275\u20131284","journal-title":"Pharmacogenomics"},{"key":"4093_CR34","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/cbdd.13596","volume":"94","author":"T Tozer","year":"2019","unstructured":"Tozer T, Heale K, Manto Chagas C et al (2019) Interdomain twists of human thymidine phosphorylase and its active-inactive conformations: binding of 5-FU and its analogues to human thymidine phosphorylase versus dihydropyrimidine dehydrogenase. Chem Biol Drug Des 94:1956\u20131972. https:\/\/doi.org\/10.1111\/cbdd.13596","journal-title":"Chem Biol Drug Des"},{"key":"4093_CR35","doi-asserted-by":"publisher","first-page":"e0175998","DOI":"10.1371\/journal.pone.0175998","volume":"12","author":"M-C Etienne-Grimaldi","year":"2017","unstructured":"Etienne-Grimaldi M-C, Boyer J-C, Beroud C et al (2017) New advances in DPYD genotype and risk of severe toxicity under capecitabine. PLoS ONE 12:e0175998. https:\/\/doi.org\/10.1371\/journal.pone.0175998","journal-title":"PLoS ONE"},{"key":"4093_CR36","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/humu.9201","volume":"22","author":"E Gross","year":"2003","unstructured":"Gross E, Ullrich T, Seck K et al (2003) Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat 22:498. https:\/\/doi.org\/10.1002\/humu.9201","journal-title":"Hum Mutat"},{"key":"4093_CR37","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.bbadis.2016.01.009","volume":"1862","author":"ABP van Kuilenburg","year":"2016","unstructured":"van Kuilenburg ABP, Meijer J, Tanck MWT et al (2016) Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene. Biochim Biophys Acta Mol Basis Dis 1862:754\u2013762. https:\/\/doi.org\/10.1016\/j.bbadis.2016.01.009","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"4093_CR38","doi-asserted-by":"publisher","first-page":"931","DOI":"10.2217\/pgs.09.28","volume":"10","author":"U Amstutz","year":"2009","unstructured":"Amstutz U, Farese S, Aebi S, Largiad\u00e8r CR (2009) Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 10:931\u2013944. https:\/\/doi.org\/10.2217\/pgs.09.28","journal-title":"Pharmacogenomics"},{"key":"4093_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/pgs.15.146","volume":"17","author":"M Del Re","year":"2016","unstructured":"Del Re M, Quaquarini E, Sottotetti F et al (2016) Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant. Pharmacogenomics 17:5\u20139. https:\/\/doi.org\/10.2217\/pgs.15.146","journal-title":"Pharmacogenomics"},{"key":"4093_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1136\/gutjnl-2013-306571","volume":"64","author":"D Rosmarin","year":"2015","unstructured":"Rosmarin D, Palles C, Pagnamenta A et al (2015) A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut 64:111\u2013120. https:\/\/doi.org\/10.1136\/gutjnl-2013-306571","journal-title":"Gut"},{"key":"4093_CR41","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.2217\/pgs-2017-0118","volume":"18","author":"M Pellicer","year":"2017","unstructured":"Pellicer M, Garc\u00eda-Gonz\u00e1lez X, Garc\u00eda MI et al (2017) Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity. Pharmacogenomics 18:1215\u20131223. https:\/\/doi.org\/10.2217\/pgs-2017-0118","journal-title":"Pharmacogenomics"},{"key":"4093_CR42","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41397-019-0077-1","volume":"19","author":"M Del Re","year":"2019","unstructured":"Del Re M, Cinieri S, Michelucci A et al (2019) DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenom J 19:556\u2013563. https:\/\/doi.org\/10.1038\/s41397-019-0077-1","journal-title":"Pharmacogenom J"},{"key":"4093_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/S41416-019-0423-8","author":"F Iachetta","year":"2019","unstructured":"Iachetta F, Romagnani A et al (2019) The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case\u2013control Study. Br J Cancer. https:\/\/doi.org\/10.1038\/S41416-019-0423-8","journal-title":"Br J Cancer"},{"key":"4093_CR44","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaoncol.2015.5392","volume":"2","author":"V Boige","year":"2016","unstructured":"Boige V, Vincent M, Alexandre P et al (2016) DPYD genotyping to predict adverse events following treatment with flourouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial. JAMA Oncol 2:655\u2013662. https:\/\/doi.org\/10.1001\/jamaoncol.2015.5392","journal-title":"JAMA Oncol"},{"key":"4093_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.phrs.2017.03.021","volume":"120","author":"M Pellicer","year":"2017","unstructured":"Pellicer M, Garc\u00eda-Gonz\u00e1lez X, Garc\u00eda MI et al (2017) Identification of new SNPs associated with severe toxicity to capecitabine. Pharmacol Res 120:133\u2013137. https:\/\/doi.org\/10.1016\/j.phrs.2017.03.021","journal-title":"Pharmacol Res"},{"key":"4093_CR46","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.18632\/oncotarget.3289","volume":"6","author":"X Garc\u00eda-Gonz\u00e1lez","year":"2015","unstructured":"Garc\u00eda-Gonz\u00e1lez X, Cortejoso L, Garc\u00eda MI et al (2015) Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget 6:6422\u20136430. https:\/\/doi.org\/10.18632\/oncotarget.3289","journal-title":"Oncotarget"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04093-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-020-04093-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-020-04093-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T23:38:21Z","timestamp":1623368301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-020-04093-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4093"],"URL":"https:\/\/doi.org\/10.1007\/s00280-020-04093-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"assertion":[{"value":"7 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest. The funders had no role in the design of the study, in the collection, analysis, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}